02181 邁博藥業—Ｂ
按盘价 
0.365 +0.030 (+8.955%) 盈利能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 资产回报率 (%) | -21.445% | -23.200% | -28.284% | -14.427% | -21.664% |
| 股东资金回报率 (%) | -69.094% | -42.041% | -39.333% | -19.081% | -31.080% |
| 资本运用回报率 (%) | -29.126% | -28.914% | -43.878% | -19.224% | -17.984% |
边际利润分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 毛利率 (%) | 86.321% | 72.504% | 79.758% | N/A | N/A |
| 未计利息、税项、折旧及摊销前利润率 (%) | -159.743% | -272.656% | -298.518% | N/A | N/A |
| 税前边际利润率 (%) | -240.195% | -377.015% | -351.999% | N/A | N/A |
| 纯利率 (%) | -240.195% | -377.015% | -351.999% | N/A | N/A |
变现能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 流动比率 (X) | 1.082 X | 1.068 X | 1.054 X | 2.809 X | 3.533 X |
| 速动比率 (X) | 0.760 X | 0.532 X | 0.828 X | 2.644 X | 3.451 X |
财务杠杆分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 总负债 / 总资产比率 (%) | 80.187% | 56.301% | 33.106% | 24.208% | 24.545% |
| 总债项 / 总资产比率 (%) | 25.128% | 13.769% | 5.077% | 3.469% | 7.564% |
| 净债项 / 总资产比率 (%) | 8.380% | 10.111% | -3.986% | -38.219% | -34.594% |
| 总债项 / 股东资金比率 (%) | 126.830% | 31.510% | 7.590% | 4.577% | 10.024% |
| 长期债项 / 股东资金比率 (%) | 65.745% | 28.195% | 6.048% | 3.609% | 3.333% |
| 净债项 / 股东资金比率 (%) | 42.295% | 23.138% | -5.958% | -50.426% | -45.847% |
| 净现金 / (债项) ($) | (8.67千万) | (9.28千万) | 3.59千万 | 4.44亿 | 4.83亿 |
| 每股净现金 / (债项) ($) | (0.021) | (0.022) | 0.009 | 0.108 | 0.117 |
| 总债项 / 资本运用比率 (%) | 36.182% | 17.327% | 6.872% | 4.201% | 9.379% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 存货周转率日数 (日) | 3104.689日 | 1828.062日 | 942.447日 | -- | -- |
| 应收贸易帐周转率日数 (日) | 60.627日 | 33.698日 | 3.492日 | N/A | N/A |
| 应付贸易帐周转率日数 (日) | 55.692日 | 96.103日 | 38.151日 | N/A | N/A |
| 备注： | 实时报价更新时间为05/11/2024 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | RMB -97,569,000 |
| 增长率 | -2.430% |
| 每股盈利/(亏损) | RMB -0.020 |
| 每股账面资产净值 (¥) | RMB 0.028 |